---
title: upfront treatment of acute myelogenous leukemia (AML)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[acute myelogenous leukemia (AML)]]

# upfront treatment of acute myelogenous leukemia (AML)

## [[InductionÂ 7+3|ä»€éº¼æ˜¯ä¸ƒåŠ ä¸‰?]]

## FLT3-ITD/TKD mutation

- 7+3+ [[midostaurin]] ğŸ‘‰ âŒ FLT3
- [[flt3.md|FLT3]]

## Core-binding factor

t(8;21) or inv(16): 7+3 Â± [[gemtuzumab ozogamicin|GOæ˜¯CDå¤šå°‘çš„inhitbitor?]] (CD33)

## 2Â° AML or w/ MDS-related changes

- CPX-351 (liposomal Ara-C & daunorubicin)

---

- <60 y: 7+3 (high-dose daunorubicin 90 mg/m2);
- > 60 y: dauno 60 mg/m2

---

## Regimens forÂ **unfit**

(may include age â‰¥75 y or < 75y w/ ECOG â‰¥3 or severe cardiac or pulmonary comorbidity;Â LeukemiaÂ 2013;27:997)

- Azacitadine + venetoclax (Bcl2 inhibitor)Â (NEJMÂ 2020;383:617)

[[IDH1_IDH2Â mutation]]: ivosidenib or enasedinib
